CANDEL THERAPEUTICS, INC. (CADL) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
14/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinCADL / S&P 110.20% / 15.20% |
LoseCADL / S&P CADL unavailable / 15.00% |
WinCADL / S&P 108.82% / 50.40% |
| 2026-Q10/3 |
LoseCADL / S&P -13.27% / -4.33% |
LoseCADL / S&P CADL unavailable / 11.30% |
LoseCADL / S&P -25.56% / 27.70% |
| 2025-Q41/3 |
WinCADL / S&P 10.78% / 2.65% |
LoseCADL / S&P CADL unavailable / 9.00% |
LoseCADL / S&P -58.62% / 13.40% |
| 2025-Q30/3 |
LoseCADL / S&P 0.79% / 8.12% |
LoseCADL / S&P CADL unavailable / 4.61% |
LoseCADL / S&P -67.63% / 13.45% |
| 2025-Q20/3 |
LoseCADL / S&P -10.44% / 10.94% |
LoseCADL / S&P CADL unavailable / 4.83% |
LoseCADL / S&P -59.76% / 10.63% |
| 2025-Q10/3 |
LoseCADL / S&P -34.91% / -4.27% |
LoseCADL / S&P CADL unavailable / 4.98% |
LoseCADL / S&P 3.91% / 10.57% |
| 2024-Q42/3 |
WinCADL / S&P 25.25% / 2.41% |
LoseCADL / S&P CADL unavailable / 5.25% |
WinCADL / S&P 33.85% / 6.15% |
| 2024-Q32/3 |
WinCADL / S&P 11.77% / 5.89% |
LoseCADL / S&P CADL unavailable / 5.89% |
WinCADL / S&P 58.72% / 6.11% |
| 2024-Q22/3 |
WinCADL / S&P 292.41% / 4.28% |
LoseCADL / S&P CADL unavailable / 5.38% |
WinCADL / S&P 53.64% / 5.12% |
| 2024-Q11/3 |
LoseCADL / S&P 7.48% / 10.56% |
LoseCADL / S&P CADL unavailable / 5.71% |
WinCADL / S&P 40.66% / 5.59% |
| 2023-Q42/3 |
WinCADL / S&P 59.78% / 11.69% |
LoseCADL / S&P CADL unavailable / 6.81% |
WinCADL / S&P 103.12% / 7.78% |
| 2023-Q30/3 |
LoseCADL / S&P -26.98% / -3.27% |
LoseCADL / S&P CADL unavailable / 7.52% |
LoseCADL / S&P -2825.00% / -5.03% |
| 2023-Q21/3 |
LoseCADL / S&P -6.67% / 8.74% |
LoseCADL / S&P CADL unavailable / 9.50% |
WinCADL / S&P 214.29% / -8.57% |
| 2023-Q10/3 |
LoseCADL / S&P -24.58% / 7.50% |
LoseCADL / S&P CADL unavailable / 10.77% |
LoseCADL / S&P -45.51% / -15.69% |
| 2022-Q40/3 |
LoseCADL / S&P -42.99% / 7.56% |
LoseCADL / S&P 0.00% / 11.88% |
LoseCADL / S&P CADL unavailable / -17.99% |
| 2022-Q31/3 |
WinCADL / S&P -3.09% / -4.88% |
LoseCADL / S&P 0.00% / 13.47% |
LoseCADL / S&P CADL unavailable / -1.41% |
| 2022-Q20/3 |
LoseCADL / S&P -36.35% / -16.10% |
LoseCADL / S&P 0.00% / 13.71% |
LoseCADL / S&P CADL unavailable / 11.04% |
| 2022-Q10/3 |
LoseCADL / S&P -34.91% / -4.60% |
LoseCADL / S&P 0.00% / 15.97% |
LoseCADL / S&P CADL unavailable / 42.23% |
| 2021-Q40/3 |
LoseCADL / S&P -27.86% / 11.03% |
LoseCADL / S&P CADL unavailable / 15.00% |
LoseCADL / S&P CADL unavailable / 96.40% |
| 2021-Q30/3 |
LoseCADL / S&P CADL unavailable / 0.58% |
LoseCADL / S&P CADL unavailable / 10.77% |
LoseCADL / S&P CADL unavailable / 69.42% |
| 2021-Q20/3 |
LoseCADL / S&P CADL unavailable / 8.55% |
LoseCADL / S&P CADL unavailable / 6.58% |
LoseCADL / S&P CADL unavailable / 51.81% |
| 2021-Q10/3 |
LoseCADL / S&P CADL unavailable / 6.17% |
LoseCADL / S&P CADL unavailable / -1.06% |
LoseCADL / S&P CADL unavailable / 7.39% |
| 2020-Q40/3 |
LoseCADL / S&P CADL unavailable / 12.15% |
LoseCADL / S&P CADL unavailable / -3.72% |
LoseCADL / S&P CADL unavailable / -33.42% |
| 2020-Q30/3 |
LoseCADL / S&P CADL unavailable / 8.93% |
LoseCADL / S&P CADL unavailable / -2.04% |
LoseCADL / S&P CADL unavailable / -27.10% |
| 2020-Q20/3 |
LoseCADL / S&P CADL unavailable / 20.54% |
LoseCADL / S&P CADL unavailable / -0.46% |
LoseCADL / S&P CADL unavailable / -27.11% |
| 2020-Q10/3 |
LoseCADL / S&P CADL unavailable / -19.60% |
LoseCADL / S&P CADL unavailable / 3.47% |
LoseCADL / S&P CADL unavailable / -14.75% |
| 2019-Q40/3 |
LoseCADL / S&P CADL unavailable / 9.07% |
LoseCADL / S&P CADL unavailable / 5.36% |
LoseCADL / S&P CADL unavailable / 2.99% |
| 2019-Q30/3 |
LoseCADL / S&P CADL unavailable / 1.70% |
LoseCADL / S&P CADL unavailable / 5.02% |
LoseCADL / S&P CADL unavailable / 0.21% |
| 2019-Q20/3 |
LoseCADL / S&P CADL unavailable / 4.30% |
LoseCADL / S&P CADL unavailable / 6.64% |
LoseCADL / S&P CADL unavailable / 8.65% |
| 2019-Q10/3 |
LoseCADL / S&P CADL unavailable / 13.65% |
LoseCADL / S&P CADL unavailable / 8.12% |
LoseCADL / S&P CADL unavailable / 14.29% |
| 2018-Q40/3 |
LoseCADL / S&P CADL unavailable / -13.52% |
LoseCADL / S&P CADL unavailable / 9.05% |
LoseCADL / S&P CADL unavailable / 18.23% |
| 2018-Q30/3 |
LoseCADL / S&P CADL unavailable / 7.71% |
LoseCADL / S&P CADL unavailable / 10.21% |
LoseCADL / S&P CADL unavailable / 19.06% |
| 2018-Q20/3 |
LoseCADL / S&P CADL unavailable / 3.43% |
LoseCADL / S&P CADL unavailable / 9.03% |
LoseCADL / S&P CADL unavailable / 14.46% |
| 2018-Q10/3 |
LoseCADL / S&P CADL unavailable / -0.76% |
LoseCADL / S&P CADL unavailable / 7.68% |
LoseCADL / S&P CADL unavailable / 12.46% |
| 2017-Q40/3 |
LoseCADL / S&P CADL unavailable / 6.64% |
LoseCADL / S&P CADL unavailable / 7.03% |
LoseCADL / S&P CADL unavailable / 13.82% |
| 2017-Q30/3 |
LoseCADL / S&P CADL unavailable / 4.48% |
LoseCADL / S&P CADL unavailable / 5.68% |
LoseCADL / S&P CADL unavailable / 17.57% |
| 2017-Q20/3 |
LoseCADL / S&P CADL unavailable / 3.09% |
LoseCADL / S&P CADL unavailable / 4.83% |
LoseCADL / S&P CADL unavailable / 17.74% |
| 2017-Q10/3 |
LoseCADL / S&P CADL unavailable / 6.07% |
LoseCADL / S&P CADL unavailable / 3.67% |
LoseCADL / S&P CADL unavailable / 13.32% |
| 2016-Q40/3 |
LoseCADL / S&P CADL unavailable / 3.82% |
LoseCADL / S&P CADL unavailable / 2.09% |
LoseCADL / S&P CADL unavailable / 7.05% |
| 2016-Q30/3 |
LoseCADL / S&P CADL unavailable / 3.85% |
LoseCADL / S&P CADL unavailable / 0.20% |
LoseCADL / S&P CADL unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CADL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 137.48% | 20.78% |
| Annualized return | 137.48% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CADL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 72.52% | 83.14% |
| Annualized return | 11.52% | 12.86% |
10Y · 2021-07-27 to 2026-08-27
| Metric | CADL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 96.43% | 319.30% |
| Annualized return | 6.98% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |